Prevalence of Metabolic Syndrome in Mild Psoriasis
- Conditions
- Health Condition 1: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2023/11/059877
- Lead Sponsor
- Dr Sathish Suriyaprakasam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients must be diagnosed with mild psoriasis, defined as having a body surface area (BSA) of less than 10%.
Controls: Patients attending Dermatology OPD/STD OPD due to the disorders neither associated with nor prone to develop metabolic syndrome such as keloid, eczema, Sexually transmitted infections and normal patient attenders.
Patients with psoriasis >10% BSA
Patients on phototherapy and systemic medications for psoriasis
Patients with Nail psoriasis, Psoriatic arthritis
Patients who are currently taking medications for any medical condition that may affect the prevalence of Metabolic syndrome.
Patients with pro-inflammatory skin conditions such as Acne, Atopic dermatitis, Alopecia, lichen planus, vitiligo, autoimmune disorders.
Patients who are not willing to consent for this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To estimate the prevalence of Metabolic syndrome in Mild psoriasisTimepoint: Single cross sectional assessment over a study period of one year
- Secondary Outcome Measures
Name Time Method To elicit the variations in prevalence of metabolic syndrome as per age, gender, duration of psoriasis, socio-economic status, physical activity and dietary habitsTimepoint: Single cross sectional assessment over a study period of one year